ライフサイエンスコーパス: ischaemic stroke

1 Hg; p=0.0007 for difference from decrease in ischaemic stroke).

2 enhancing clinical recovery of patients with ischaemic stroke.

3 ic intracranial haemorrhage, and symptomatic ischaemic stroke.

4 cranial haemorrhage and 1.23 (1.08-1.40) for ischaemic stroke.

5 icacy of oral S44189 in patients with recent ischaemic stroke.

6 ted with an increased frequency of recurrent ischaemic stroke.

7 plays a fundamental part in the occurence of ischaemic stroke.

8 solute risk of intracranial haemorrhage than ischaemic stroke.

9 VSIAs, and the most common complication was ischaemic stroke.

10 in K antagonists (VKAs) to prevent recurrent ischaemic stroke.

11 in patients treated with alteplase for acute ischaemic stroke.

12 rence of the coronary heart disease event or ischaemic stroke.

13 fe and well tolerated in patients with acute ischaemic stroke.

14 ertensive disease, myocardial infarction and ischaemic stroke.

15 icity in the subacute to chronic phase after ischaemic stroke.

16 hted imaging (DWI) typically indicates acute ischaemic stroke.

17 n the diagnostic evaluation of patients with ischaemic stroke.

18 acy and safety of thrombolytic treatment for ischaemic stroke.

19 ting the best therapy in patients with acute ischaemic stroke.

20 cule alpha4 integrin, in patients with acute ischaemic stroke.

21 the major venous imaging-based biomarkers in ischaemic stroke.

22 tly correlates with stroke outcomes in acute ischaemic stroke.

23 l patterns associated with headache in acute ischaemic stroke.

24 ated to the development of headache in acute ischaemic stroke.

25 on motor recovery in patients after an acute ischaemic stroke.

26 ar thrombectomy in patients who had an acute ischaemic stroke.

27 or untreated control) in patients with acute ischaemic stroke.

28 rd care or standard care alone within 6 h of ischaemic stroke.

29 onset, characteristics and outcome of acute ischaemic stroke.

30 outcome when delivered within 4.5 h of acute ischaemic stroke.

31 f pH-weighted imaging in patients with acute ischaemic stroke.

32 ppocampal CA1 region is highly vulnerable to ischaemic stroke.

33 on of tissue plasminogen activator (tPA) for ischaemic stroke.

34 he only approved medical treatment for acute ischaemic stroke.

35 prospective cohort of 12 patients with acute ischaemic stroke.

36 (AD) increases dramatically in patients with ischaemic stroke.

37 non-fatal, and for haemorrhagic rather than ischaemic stroke.

38 We identified 96 cases of arterial ischaemic stroke.

39 3Kdelta as a potential therapeutic target in ischaemic stroke.

40 orrhage (regression p<0.0001) but not before ischaemic stroke.

41 upper limb motor deficits 2-13 months after ischaemic stroke.

42 ts with transient ischaemic attack and minor ischaemic stroke.

43 rage from a cohort of 18 patients with acute ischaemic stroke.

44 patients treated with alteplase after acute ischaemic stroke.

45 emorrhage, and 41% of recurrent strokes were ischaemic stroke.

46 alone in patients at high risk for recurrent ischaemic stroke.

47 independently predicts early mortality after ischaemic stroke.

48 d-to-moderate atrial fibrillation-associated ischaemic stroke.

49 ceiving alteplase for mild-to-moderate acute ischaemic stroke.

50 emorrhagic complications after AF-associated ischaemic stroke.

51 the rate of first recurrence of symptomatic ischaemic stroke.

52 to the severity and imaging features of the ischaemic stroke.

53 are now thought to comprise about 25% of all ischaemic strokes.

54 ogen activator) alone for moderate or severe ischaemic strokes.

55 p=0.005), particularly of disabling or fatal ischaemic stroke (0.64, 0.49-0.84, p=0.0010).

56 85-0.98), a non-significant 9% lower risk of ischaemic stroke (0.91, 0.82-1.01), and a 32% lower risk

57 k 1.58, 95% CI 1.36-1.84, p<0.0001) than for ischaemic stroke (1.27, 1.13-1.43, p=0.0001).

58 jor coronary event (2.44, 95% CI 2.18-2.73), ischaemic stroke (1.68, 95% CI 1.60-1.77), and intracere

59 sease (adjusted HR 2.98 [95% CI 2.76-3.22]), ischaemic stroke (1.72 [1.52-1.95]), stable angina (1.62

60 ecific hazard ratio 2.98, 95% CI 2.76-3.22), ischaemic stroke (1.72, 1.52-1.95), stable angina (1.62,

61 , 0.43-1.00; p=0.05), but significantly more ischaemic strokes (1.28, 1.02-1.60; p=0.045).

62 ]) and mortality at 5 years was 17% ([17-18] ischaemic stroke 16% [15-16], intracerebral haemorrhage

63 site outcome of intracranial haemorrhage and ischaemic stroke; 2.45 (1.82-3.29) for intracranial haem

64 Of the 597 disabling/fatal incident ischaemic strokes, 369 occurred at age >/=80 years, of w

65 41% (41-42) had recurrent stroke at 5 years (ischaemic stroke 41% [41-42], intracerebral haemorrhage

66 years; and for >=20 cerebral microbleeds, 73 ischaemic strokes [46-108] per 1000 patient-years vs 39

67 28-day mortality was 3% (95% CI 3-4) for ischaemic stroke, 47% (46-48)for intracerebral haemorrha

68 8 (80%) of the incident cases of stroke were ischaemic stroke, 7440 (16%) were intracerebral haemorrh

69 stimulation is safe for patients with acute ischaemic stroke 8-24 h after onset, who are ineligible

70 the PAR for all stroke worldwide (91.5% for ischaemic stroke, 87.1% for intracerebral haemorrhage),

71 After a first ischaemic stroke, 91% of recurrent strokes were also isc

72 ge (for ten or more cerebral microbleeds, 64 ischaemic strokes [95% CI 48-84] per 1000 patient-years

73 Acute ischaemic stroke accounts for 6.5 million deaths per yea

74 Some further reduction in risk of ischaemic stroke accrued for aspirin only versus control

75 ies reporting the risks of recurrent ICH and ischaemic stroke after ICH found no significant differen

76 c stroke, 91% of recurrent strokes were also ischaemic stroke; after an intracerebral haemorrhage, 56

77 le-blind, phase 2 study, patients with acute ischaemic stroke (aged 18-85 years) from 30 US and Europ

78 11 stroke survivors with a first-ever TIA or ischaemic stroke, aged 18-50 years.

79 Ninety-six children with an arterial ischaemic stroke (AIS) and 43 with a haemorrhagic stroke

80 Arterial ischaemic stroke (AIS) is an important cause of acquired

81 BB) isoform increased in patients with acute ischaemic stroke (AIS).

82 -HAs) on brain MRI and prognosis after acute ischaemic stroke (AIS).

83 unctional MRI data of 31 patients with acute ischaemic stroke and 17 age-matched healthy control subj

84 from 32 countries (13 447 cases [10 388 with ischaemic stroke and 3059 intracerebral haemorrhage] and

85 ults (aged 18-85 years) who had a first-ever ischaemic stroke and a motor deficit of the upper extrem

86 ged 18-83 years with moderately severe acute ischaemic stroke and a National Institutes of Health Str

87 In patients with ischaemic stroke and AF, predictors of d-sICH are differ

88 mostly observational data from patients with ischaemic stroke and atrial fibrillation treated with he

89 e extension of leukoaraiosis and severity of ischaemic stroke and brain atrophy.

90 ain barrier, namely malignant brain tumours, ischaemic stroke and haemorrhagic traumatic contusion.

91 f the effect of aspirin on risk of recurrent ischaemic stroke and how this differs by severity at bas

92 n is based on a balance between reduction in ischaemic stroke and increase in major bleeding.

93 Stroke, including acute ischaemic stroke and intracerebral haemorrhage, results

94 s and brain imaging to differentiate between ischaemic stroke and intracerebral haemorrhage.

95 a young transient ischaemic attack (TIA) or ischaemic stroke and its association with functional out

96 en a wide range of haematological traits and ischaemic stroke and its subtypes.

97 acerbate blood-brain barrier breakdown after ischaemic stroke and lead to lethal haemorrhagic transfo

98 ional outcome when given to patients who had ischaemic stroke and major cerebral artery occlusion bey

99 ts from 77 hospitals in 17 countries who had ischaemic stroke and occlusion or high-grade stenosis in

100 High rates of recurrent ischaemic stroke and other cardiovascular events mandate

101 trointestinal bleeding), patients with acute ischaemic stroke and patients with an intracardiac throm

102 d one ischaemic stroke) and two PCC related (ischaemic stroke and pulmonary embolism).

103 ligible patients (age >=18 years) with acute ischaemic stroke and systolic blood pressure 150 mm Hg o

104 to initiate DOAC administration after recent ischaemic stroke and whether the timing should differ ac

105 002 and 31 June 2011 for space-occupying MCA ischaemic stroke and who underwent DHC.

106 They were compared with 1384 strokes (1193 ischaemic strokes and 191 intracerebral haemorrhages) in

107 We collected data on 86 strokes (81 ischaemic strokes and 5 intracerebral haemorrhages) in p

108 st, a relative increase in the proportion of ischaemic strokes and a decline in haemorrhagic strokes.

109 tion, coronary revascularization or presumed ischaemic stroke) and the interaction with ADCY9 rs19673

110 xpansion, one anaphylactic reaction, and one ischaemic stroke) and two PCC related (ischaemic stroke

111 ed to oxygen glucose deprivation (a model of ischaemic stroke), and in hippocampal pyramidal neuron c

112 vs 101 [47%] of 213 patients with recurrent ischaemic stroke), and outnumbered disabling or fatal in

113 nt of all-cause stroke or systemic embolism, ischaemic stroke, and all-cause mortality.

114 only the first few days after TIA and minor ischaemic stroke, and observational studies show substan

115 infarct size, in preclinical models of acute ischaemic stroke, and showed potential benefit in a pilo

116 It is well protected against ischaemic stroke, and so there is relatively little neur

117 improved clinical outcome in patients after ischaemic stroke, and thus S44819 cannot be recommended

118 t association of rs2293871 with small vessel ischaemic stroke, and two blood expression quantitative

119 rimary intracerebral haemorrhage and lacunar ischaemic stroke are acute manifestations of progressive

120 eriods, so the long-term outcomes post-minor ischaemic stroke are unclear.

121 Cryptogenic (of unknown cause) ischaemic strokes are now thought to comprise about 25%

122 rd of transient ischaemic attacks (TIAs) and ischaemic strokes are of undetermined cause (ie, cryptog

123 About 13-26% of all acute ischaemic strokes are related to non-valvular atrial fib

124 ew oral anticoagulants for the prevention of ischaemic stroke, as well as bleeding risk assessment, m

125 to later oral anticoagulation with DOACs in ischaemic stroke associated with atrial fibrillation are

126 on-fatal myocardial infarction, or non-fatal ischaemic stroke) associated with cumulative burden of r

127 The reduction in risk of recurrent ischaemic stroke at 14 days was most evident in patients

128 were aged 18 years or older with a disabling ischaemic stroke at the time of randomisation, had been

129 Ischaemic stroke at young age is an increasing problem i

130 re was no difference in the risk of arterial ischaemic stroke between sexes (crude incidence 1.60 per

131 In animal models of acute ischaemic stroke, blocking of the leukocyte-endothelium

132 lteplase is effective for treatment of acute ischaemic stroke but debate continues about its use afte

133 subsequent intracranial haemorrhage than for ischaemic stroke, but the absolute risk of ischaemic str

134 intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure

135 Headache is a common symptom in acute ischaemic stroke, but the underlying mechanisms are inco

136 Aspirin reduced the 6 week risk of recurrent ischaemic stroke by about 60% (84 of 8452 participants i

137 0.32-0.55, p<0.0001) and disabling or fatal ischaemic stroke by about 70% (36 of 8452 vs 110 of 7326

138 three studies, an extension cohort of 12 577 ischaemic stroke cases and 25 643 controls from NINDS-Si

139 INDS-SiGN, and a validation cohort of 10 307 ischaemic stroke cases and 29 326 controls from METASTRO

140 Ischaemic stroke caused by arterial occlusion is respons

141 standard medical care in patients with acute ischaemic stroke caused by occlusion of arteries of the

142 In these trials, patients with acute ischaemic stroke caused by occlusion of the proximal ant

143 my is of benefit to most patients with acute ischaemic stroke caused by occlusion of the proximal ant

144 anial stenosis conveyed an increased risk of ischaemic stroke compared with no intracranial stenosis

145 'cryptogenic' stroke accounts for 30-40% of ischaemic strokes despite extensive diagnostic evaluatio

146 Acute ischaemic stroke disturbs healthy brain organization, pr

147 ety of endovascular treatment (EVT) in acute ischaemic stroke due to cervical and/or cerebral arteria

148 t countries, we enrolled patients with acute ischaemic stroke due to large vessel occlusion within a

149 vide timely treatment to patients with acute ischaemic stroke due to large vessel occlusion.

150 rt oral anticoagulant (OAC) in patients with ischaemic stroke due to non-valvular atrial fibrillation

151 evaluation study, adults with supratentorial ischaemic stroke eligible for intravenous thrombolysis w

152 rial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial fi

153 atomical distribution or burden, the rate of ischaemic stroke exceeded that of intracranial haemorrha

154 intravenous alteplase for treatment of acute ischaemic stroke for which data were available.

155 morrhage but this effect was less marked for ischaemic stroke (for five or more cerebral microbleeds,

156 acranial haemorrhage vs 1.47 [1.19-1.80] for ischaemic stroke; for ten or more cerebral microbleeds,

157 icipants were patients presenting with acute ischaemic stroke from anterior circulation large-vessel

158 hire, UK, among patients with a first TIA or ischaemic stroke from April 1, 2002, to March 31, 2014,

159 mes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortali

160 Management of ischaemic stroke has greatly advanced, with rapid reperf

161 ON THIS ARTICLE: About 20% of patients with ischaemic stroke have a preceding transient ischaemic at

162 pulation-based studies of childhood arterial ischaemic stroke have been undertaken.

163 tive trials of endovascular thrombectomy for ischaemic stroke have provided level 1 evidence for impr

164 n, patients with high-risk non-cardioembolic ischaemic stroke identified on MRI were randomly assigne

165 tine ganglion stimulation 8-24 h after acute ischaemic stroke improved functional outcome.

166 and clinical features of childhood arterial ischaemic stroke in a population-based cohort.

167 Acute ischaemic stroke in brain areas contributing to male sex

168 5% CI 1.04-1.96), the risk of same-territory ischaemic stroke in patients with 70-99% symptomatic int

169 to commence DOAC administration after acute ischaemic stroke in patients with atrial fibrillation.

170 ature through a PubMed search, we found that ischaemic stroke in people with migraine is strongly ass

171 t increased risk of myocardial infarction or ischaemic stroke in the absence of established cardiovas

172 higher proportion of patients had recurrent ischaemic stroke in the intra-arterial treatment plus us

173 t pooled data from consecutive patients with ischaemic stroke in the setting of AF from stroke regist

174 Ischaemic stroke induces endogenous repair processes tha

175 monitoring cardiovascular disease (including ischaemic stroke, intracerebral haemorrhage, and myocard

176 ring the study period were recorded by type (ischaemic stroke, intracerebral haemorrhage, subarachnoi

177 Patients aged 18-85 years with acute ischaemic stroke involving cerebral cortex (National Ins

178 Arterial ischaemic stroke is an important cause of acquired brain

179 en activator (rtPA) on functional outcome in ischaemic stroke is clear, but there are some treated pa

180 Although the risk of early recurrent ischaemic stroke is high in this population, early oral

181 r ischaemic stroke, but the absolute risk of ischaemic stroke is higher than that of intracranial hae

182 te-phase systolic blood pressure after major ischaemic stroke is much closer to the accustomed long-t

183 e use of CMR in the diagnostic evaluation of ischaemic stroke is sparse.

184 Ischaemic stroke is the leading cause of severe long-ter

185 ffect of alteplase on patient survival after ischaemic stroke is the subject of debate.

186 Currently, the only approved treatment for ischaemic stroke is tissue plasminogen activator, a clot

187 ds in mortality and functional dependence by ischaemic stroke (IS) aetiological subtype over a 16-yea

188 a-scoring approach, we develop a metaGRS for ischaemic stroke (IS) and analyse this score in the UK B

189 clinical outcomes in patients with previous ischaemic stroke (IS) or ICH.

190 l links between Alzheimer's disease (AD) and Ischaemic Stroke (IS).

191 st cancer, colorectal cancer, endometriosis, ischaemic stroke, leukemia, lymphoma and osteoarthritis.

192 gy, HIF stabilisation and neuroprotection in ischaemic stroke merits further investigation.

193 ke occurs in about one in four patients with ischaemic stroke, more commonly in lacunar strokes.

194 Patients with acute ischaemic stroke (n = 100) were assessed by brain MRI at

195 U-shaped associations with the incidence of ischaemic stroke (n=14 930), intracerebral haemorrhage (

196 artial recovery, and one patient died; (iii) ischaemic strokes (n = 8) associated with a pro-thrombot

197 We included patients with acute ischaemic stroke (National Institutes of Health Stroke S

198 nt services with a lacunar or minor cortical ischaemic stroke (National Institutes of Health Stroke S

199 are records in all patients with acute major ischaemic stroke (National Institutes of Health Stroke S

200 In summary, acute ischaemic stroke not only prompted changes in connectivi

201 40-85 years) with anterior-circulation acute ischaemic stroke, not undergoing reperfusion therapy.

202 e, with transient ischaemic attack and minor ischaemic stroke occurring between March 1, 2011, and Ma

203 years with radiologically confirmed arterial ischaemic stroke occurring over a 1-year period (July 1,

204 venous alteplase on long-term survival after ischaemic stroke of participants in the Third Internatio

205 = 603); and (ii) patients with recent minor ischaemic stroke of the Mild Stroke Study (n = 155).

206 on after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% re

207 l benefit of neurothrombectomy within 6 h of ischaemic stroke onset, which has initiated a new era of

208 om disorders of the cerebrovasculature, i.e. ischaemic stroke or haemorrhage.

209 eart attack and angina) or stroke (including ischaemic stroke or haemorrhagic stroke).

210 me was the composite outcome of TIA, stroke (ischaemic stroke or intracranial haemorrhage) or death w

211 6.15), lung cancer (RR 3.78, 2.78-5.14), and ischaemic stroke or ischaemic heart disease (combined RR

212 In adjusted analyses, early OAC after acute ischaemic stroke or TIA associated with AF was not assoc

213 ong insulin-resistant patients with a recent ischaemic stroke or TIA, pioglitazone did not affect cog

214 n with cognitive impairment in patients with ischaemic stroke or TIA.

215 inception cohort study of 1490 patients with ischaemic stroke or transient ischaemic attack (TIA) and

216 Stroke (IRIS) trial, patients with a recent ischaemic stroke or transient ischaemic attack (TIA) wer

217 ed-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) wit

218 al microbleeds indicate patients with recent ischaemic stroke or transient ischaemic attack in whom t

219 atterns of cerebral microbleeds can identify ischaemic stroke or transient ischaemic attack patients

220 , or death at 90 days in patients with acute ischaemic stroke or transient ischaemic attack when asso

221 In patients with recent ischaemic stroke or transient ischaemic attack, cerebral

222 ta from cohort studies in adults with recent ischaemic stroke or transient ischaemic attack.

223 spectively recruited adult participants with ischaemic stroke or transient ischaemic attack; included

224 versus 7/358 (2%) in the early-OAC group (5 ischaemic strokes or TIAs and 2 deaths).

225 e-OAC group (2 intracranial haemorrhages, 18 ischaemic strokes or TIAs and 31 deaths (three deaths we

226 vents (myocardial infarction, heart failure, ischaemic stroke, or death) with the landmark set at 1 y

227 r with a non-cardioembolic, non-severe acute ischaemic stroke, or high-risk transient ischaemic attac

228 nts with a first transient ischaemic attack, ischaemic stroke, or myocardial infarction treated with

229 iovascular disease, ischaemic heart disease, ischaemic stroke, or peripheral arterial disease.

230 al myocardial infarction, fatal or non-fatal ischaemic stroke, or unstable angina requiring hospital

231 ic intracerebral haemorrhage) and secondary (ischaemic stroke) outcomes for up to 5 years (reported e

232 and cardiac causes were more associated with ischaemic stroke (p<0.0001).

233 s with standard care in anterior circulation ischaemic stroke patients (HERMES Collaboration).

234 In total, 5035 acute ischaemic stroke patients were enrolled.

235 We assessed functional outcome in ischaemic stroke patients with large vessel anterior cir

236 ly reduced soon after stroke onset (84 acute ischaemic stroke patients with or without intravenous tP

237 A similar inverse association was found for ischaemic stroke [prevalent CAD (OR 0.78; 95% CI 0.67, 0

238 domised trials of endovascular treatment for ischaemic stroke, published in 2013, were neutral but li

239 herapy in patients with anterior circulation ischaemic stroke, published in PubMed from Jan 1, 2010,

240 rrhage and mortality, in patients with acute ischaemic stroke receiving endovascular therapies.

241 trials included patients who had experienced ischaemic stroke recently (within the first few weeks).

242 Ischaemic stroke recurred in 29 (3%) of 932 patients (an

243 in or clopidogrel had a reduced incidence of ischaemic stroke recurrence and a similar risk of severe

244 l pruritus, trigeminal trophic syndrome, and ischaemic stroke-related itch.

245 Intravenous thrombolysis for ischaemic stroke remains underused worldwide.

246 which have been shown to be associated with ischaemic stroke risk.

247 issue atrophy of extent of leukoaraiosis and ischaemic stroke severity.

248 Secondary prevention of ischaemic stroke shares many common elements with cardio

249 Patients can present with headache, ischaemic stroke, subarachnoid haemorrhage, or symptoms

250 matological traits contribute equally to all ischaemic stroke subtypes is uncertain.

251 Among ischaemic stroke subtypes, lacunar strokes, which were o

252 In analysis of ischaemic stroke subtypes, the myeloperoxidase increasin

253 n with primary intracerebral haemorrhage and ischaemic stroke subtypes.

254 ional and novel risk factors for early-onset ischaemic stroke, such as air pollution.

255 ospective, population-based cohort of 1-year ischaemic stroke survivors (Oxford Vascular Study; 2002-

256 Intracerebral haemorrhage and small vessel ischaemic stroke (SVS) are the most acute manifestations

257 any symptomatic intracranial haemorrhage or ischaemic stroke, symptomatic intracranial haemorrhage,

258 34) children were at higher risk of arterial ischaemic stroke than were white children.

259 nt-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple

260 st and prolonged systemic immune response to ischaemic stroke that occurs in three phases: an acute p

261 In patients with ischaemic stroke, the first acute-phase systolic blood p

262 By contrast with findings in ischaemic stroke, the mean first systolic blood pressure

263 ebral haemorrhage was more likely than after ischaemic stroke to be the highest ever recorded (OR 3.4

264 small vessel disease, in a patient cohort of ischaemic stroke/transient ischaemic attack (TIA) referr

265 ecent advances in the gold standard of acute ischaemic stroke treatment, some aspects of which-aspiri

266 ith poor collaterals, in patients with acute ischaemic stroke under EVT.

267 d angiography allows a positive diagnosis of ischaemic stroke versus mimics and can identify a large

268 deaths (three deaths were as a result of new ischaemic strokes)) versus 7/358 (2%) in the early-OAC g

269 452 participants in the aspirin group had an ischaemic stroke vs 175 of 7326; hazard ratio [HR] 0.42,

270 TIA or minor stroke had a disabling or fatal ischaemic stroke vs 23 of 5726 in the control group, HR

271 The crude incidence of childhood arterial ischaemic stroke was 1.60 per 100 000 per year (95% CI 1

272 e maximum premorbid level whereas that after ischaemic stroke was 5.2 mm Hg lower (p<0.0001).

273 only therapy with proven efficacy for acute ischaemic stroke was alteplase, which is approved for us

274 Alteplase treatment within 6 h after ischaemic stroke was associated with a small, non-signif

275 The effect of aspirin on early recurrent ischaemic stroke was due partly to a substantial reducti

276 patients treated with alteplase after acute ischaemic stroke was feasible and most likely safe, but

277 least one risk factor for childhood arterial ischaemic stroke was identified in 80 (83%) cases.

278 In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of ons

279 control in secondary prevention after TIA or ischaemic stroke, we studied the effects of aspirin on t

280 ean age 60.5 +/- 10.5 years) with first-ever ischaemic strokes, we assessed erectile function after a

281 ed Rankin Scale score 2-4) 6-60 months after ischaemic stroke were implanted with single doses of 2 m

282 years) receiving tPA treatment for confirmed ischaemic stroke were included.

283 2196 alteplase-eligible patients with acute ischaemic stroke were included: 1081 in the intensive gr

284 Cases with ischaemic stroke were more likely than ischaemic control

285 rrhage is likely to exceed that of recurrent ischaemic stroke when treated with antithrombotic drugs.

286 ted with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, diabetes, apo

287 able new targets for secondary prevention of ischaemic stroke, while factor VIII and gamma' fibrinoge

288 Patients with acute ischaemic stroke who could be treated within 8 h of symp

289 We identified 578 patients with acute ischaemic stroke who received thrombectomy, 19 had sICH

290 ata from 333 consecutive patients with acute ischaemic stroke who underwent susceptibility-weighted i

291 We enrolled 4947 (99%) of 4992 patients with ischaemic stroke who were admitted to hospitals in Tyrol

292 ompare the clinical outcome of patients with ischaemic stroke with anterior large vessel occlusion tr

293 Non-GA during MT for anterior acute ischaemic stroke with current-generation stent retriever

294 months) rats treated 24 h following cortical ischaemic stroke with human NT3 delivered using a clinic

295 thrombectomy (MT) in patients who had acute ischaemic stroke with large artery occlusive anterior ci

296 nd patient is a 62-year-old woman who had an ischaemic stroke with massive haemorrhagic conversion re

297 Current treatment of ischaemic stroke with thrombolytic therapy is restricted

298 ry prevention of atrial fibrillation-related ischaemic stroke, with around half the risk of intracran

299 and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therap

300 d no effect on risk or severity of recurrent ischaemic stroke within 12 weeks (OR 0.90, 95% CI 0.65-1